MENLO PARK

Robinhood Reports First Quarter 2024 Results

Retrieved on: 
Wednesday, May 8, 2024
Transfer, Crypto, Cryptocurrency, Customer, Total, Retirement, ETF, Net, Robinhood Markets, ARPU, Active users, SBC, Entrepreneurship, Record, EPS, Gold, Marketing, MAU, Adjustment, Revenue, AUC, GAAP, Growth, Fraud

MENLO PARK, Calif., May 08, 2024 (GLOBE NEWSWIRE) -- Robinhood Markets, Inc. (“Robinhood”) (NASDAQ: HOOD) today announced financial results for the first quarter of 2024, which ended March 31, 2024.

Key Points: 
  • Record Revenues of $618 million, up 40% year-over-year and Record GAAP Diluted EPS of $0.18
    Record Net Deposits of $11.2B, including net positive transfers from every major incumbent brokerage firm
    Gold Subscribers reached a new high of 1.7 million, up 42% year-over-year
    MENLO PARK, Calif., May 08, 2024 (GLOBE NEWSWIRE) -- Robinhood Markets, Inc. (“Robinhood”) (NASDAQ: HOOD) today announced financial results for the first quarter of 2024, which ended March 31, 2024.
  • "We delivered significant revenue growth and margin expansion in Q1 as we remain focused on driving another year of profitable growth in 2024,” said Jason Warnick, Chief Financial Officer of Robinhood.
  • Robinhood UK Reaches Full Availability - Marking another step in global expansion, Robinhood rolled all eligible customers off the waitlist in March.
  • Robinhood will host a conference call to discuss its results at 2 p.m. PT / 5 p.m.

Sight Sciences to Present at the Upcoming Bank of America Healthcare Conference

Retrieved on: 
Tuesday, May 7, 2024
Standard of care, Bank, Conference, Interest

MENLO PARK, Calif., May 07, 2024 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (“Sight Sciences” or the “Company”), an eyecare technology company focused on developing and commercializing innovative, interventional technologies that elevate the standard of care, today announced it will present at the upcoming Bank of America Healthcare Conference, in Las Vegas, NV.

Key Points: 
  • MENLO PARK, Calif., May 07, 2024 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (“Sight Sciences” or the “Company”), an eyecare technology company focused on developing and commercializing innovative, interventional technologies that elevate the standard of care, today announced it will present at the upcoming Bank of America Healthcare Conference, in Las Vegas, NV.
  • Sight Sciences’ management is scheduled to present on Tuesday, May 14, 2024, at 8:15 am PT / 11:15 am ET.
  • Interested parties may access a live and archived webcast of the fireside chat on the “Investors” section of the company’s website at: investors.sightsciences.com .

Sight Sciences Reports First Quarter 2024 Financial Results and Reaffirms Full Year 2024 Financial Guidance

Retrieved on: 
Thursday, May 2, 2024
FDA, Hydrus, MIGS, Telecanthus, Nature, Refractive surgery, News, Research, Depreciation, Cataract, Security (finance), IOP, DED, Webcast, Growth, Environment, District court, Patent, Intraocular pressure, Patient, Court, Society, Judgement, Glaucoma, Alcon, Ciclosporin, Standard of care, GAAP, Pharmaceutical industry

Generated first quarter 2024 total revenue of $19.3 million, an increase of 2% compared to the same period in the prior year.

Key Points: 
  • Generated first quarter 2024 total revenue of $19.3 million, an increase of 2% compared to the same period in the prior year.
  • The jury found that Sight Sciences’ asserted patents were willfully infringed, and awarded monetary damages for past infringement.
  • Sight Sciences reaffirms revenue guidance expectations for full year 2024 of approximately $81.0 million to $85.0 million, representing growth of approximately 0% to 5% growth compared to 2023.
  • Sight Sciences' management team will host a conference call today, May 2, 2024, beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.

Getmyboat and Visa Announce Exclusive Partnership for Premium Customers

Retrieved on: 
Thursday, May 2, 2024
Business development, Travel, MENA, Partnership, Adventure, Water, Infinite

Under this partnership, Visa cardholders will enjoy exclusive offers and benefits when they book a boat day through Getmyboat.

Key Points: 
  • Under this partnership, Visa cardholders will enjoy exclusive offers and benefits when they book a boat day through Getmyboat.
  • "We are thrilled to partner with Visa to elevate the experiences of our mutual customers," said Doug Bird, VP of Sales & Business Development for Getmyboat.
  • By joining forces with Visa, Getmyboat continues to innovate and deliver unmatched value to travelers seeking unique and memorable experiences across the globe.
  • For more information about this partnership and the exclusive offers available, please visit https://www.getmyboat.com.

Exponent Reports First Quarter 2024 Financial Results

Retrieved on: 
Thursday, April 25, 2024
EXPO, Total, Safety, Health, Depreciation, Chemical industry, Transport, Wind, Engineering, Exponentiation, Tax, Farm, Classification, Electronics, GAAP, Growth, Health insurance

MENLO PARK, Calif., April 25, 2024 (GLOBE NEWSWIRE) -- Exponent, Inc. (Nasdaq: EXPO) today reported financial results for the first quarter of fiscal year 2024 ended March 29, 2024.

Key Points: 
  • MENLO PARK, Calif., April 25, 2024 (GLOBE NEWSWIRE) -- Exponent, Inc. (Nasdaq: EXPO) today reported financial results for the first quarter of fiscal year 2024 ended March 29, 2024.
  • “Exponent delivered better than expected results in the first quarter, as we grew revenues before reimbursements 7% and expanded earnings per share year over year.
  • During the first quarter of 2024, Exponent paid $15.6 million in dividends and closed the period with $168.7 million in cash and cash equivalents.
  • Exponent will discuss its financial results in more detail on a conference call today, Thursday, April 25, 2024, starting at 4:30 p.m. Eastern Time / 1:30 p.m. Pacific Time.

Exponent Declares Regular Quarterly Dividend for Q2 2024

Retrieved on: 
Thursday, April 25, 2024
EXPO, Exponentiation

MENLO PARK, Calif., April 25, 2024 (GLOBE NEWSWIRE) -- Exponent, Inc. (Nasdaq: EXPO) today announced that its Board of Directors has declared a quarterly cash dividend of $0.28 per share of common stock to be paid on June 21, 2024 to all common stockholders of record as of June 7, 2024.

Key Points: 
  • MENLO PARK, Calif., April 25, 2024 (GLOBE NEWSWIRE) -- Exponent, Inc. (Nasdaq: EXPO) today announced that its Board of Directors has declared a quarterly cash dividend of $0.28 per share of common stock to be paid on June 21, 2024 to all common stockholders of record as of June 7, 2024.
  • Exponent has paid, and expects to continue to pay, quarterly dividends each year in March, June, September, and December.
  • Future declarations of quarterly dividends and the establishment of future record and payment dates are subject to the final determination of Exponent’s Board of Directors.
  • “As industries evolve and complexities grow, Exponent is well-positioned to address these prospective challenges, enabling us to drive sustainable long-term growth.”

Joshu Achieves SOC 2 Type II Recertification

Retrieved on: 
Thursday, April 25, 2024
Certified Public Accountant, Certification, Policy, Insurance, SOC 2, Automation, DNA, American Institute, SOC, Fintech, AICPA, System and Organization Controls, Organization

The American Institute of Certified Public Accountants (AICPA) SOC 2 certification assures Joshu customers the highest recognized standards of information security compliance in the world are in place.

Key Points: 
  • The American Institute of Certified Public Accountants (AICPA) SOC 2 certification assures Joshu customers the highest recognized standards of information security compliance in the world are in place.
  • The SOC 2 Type II certification specifically ensures all information stored on the Joshu Platform is secured to the design and structure of the proper controls, policies, and procedures.
  • “Security was built into the DNA of the Joshu platform,” said Shimi Bornstein, CTO and co-founder of Joshu .
  • “As more insurance organizations rely on Joshu for complete automation of the insurance policy lifecycle, the importance of remaining SOC 2 compliance was evident.

Corcept Therapeutics to Announce First Quarter Financial Results, Provide Corporate Update and Host Conference Call

Retrieved on: 
Wednesday, April 24, 2024
PIN

MENLO PARK, Calif., April 24, 2024 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT) today announced it will report first quarter financial results and provide a corporate update on May 1, 2024.

Key Points: 
  • MENLO PARK, Calif., April 24, 2024 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT) today announced it will report first quarter financial results and provide a corporate update on May 1, 2024.
  • The company will also host a conference call that day at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time).
  • Participants must register in advance of the conference call by clicking here.
  • Upon registering, each participant will receive a dial-in number, and a unique access PIN.

Corcept Announces Positive Results From Open-Label Portion of Pivotal Phase 3 GRACE Trial in Patients With Cushing’s Syndrome

Retrieved on: 
Monday, April 22, 2024
GRACE, Hyperglycemia, University, Patient, Syndrome, SBP, Adrenal insufficiency, Safety, NDA, Waist, Ann Arbor, Michigan, MD, Doctor of Philosophy, Vaginal bleeding, DSM-IV codes, Doctor of Pharmacy, Diabetes, Hypertension, Metabolism, Internal medicine, Endocrinology, Division, Deficit spending, DBP, Pharmaceutical industry

In the “open-label” phase, 152 patients with Cushing’s syndrome and either hypertension, hyperglycemia or both received relacorilant for 22 weeks.

Key Points: 
  • In the “open-label” phase, 152 patients with Cushing’s syndrome and either hypertension, hyperglycemia or both received relacorilant for 22 weeks.
  • GRACE’s primary endpoint is maintenance of blood pressure control in the “randomized withdrawal” phase, with maintenance of glycemic control as the key secondary endpoint.
  • Other key secondary and exploratory endpoints in the randomized withdrawal phase include changes in weight, waist circumference, cognitive impairment and Cushing’s Quality of Life score.
  • Patients in the open-label phase exhibited clinically meaningful and statistically significant improvements in hypertension, hyperglycemia and other key secondary and exploratory endpoints.

Sight Sciences to Report First Quarter Financial Results on May 2, 2024

Retrieved on: 
Thursday, April 18, 2024
News, Standard of care, Webcast

MENLO PARK, Calif., April 18, 2024 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (“Sight Sciences” or the “Company”), an eyecare technology company focused on developing and commercializing innovative, interventional technologies that elevate the standard of care, today announced it will report financial results for the first quarter ended March 31, 2024, after the market close on Thursday, May 2, 2024.

Key Points: 
  • MENLO PARK, Calif., April 18, 2024 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (“Sight Sciences” or the “Company”), an eyecare technology company focused on developing and commercializing innovative, interventional technologies that elevate the standard of care, today announced it will report financial results for the first quarter ended March 31, 2024, after the market close on Thursday, May 2, 2024.
  • The Company’s management will discuss the results during a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.
  • Investors interested in listening to the conference call may do so by accessing a live and archived webcast of the event at www.sightsciences.com , on the Investors page in the News & Events section.
  • The webcast will be available for replay for at least 90 days after the event.